Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $52,265.20 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Day One Biopharmaceuticals Trading Up 1.6 %

Day One Biopharmaceuticals stock opened at $12.43 on Monday. Day One Biopharmaceuticals, Inc. has a 12-month low of $11.13 and a 12-month high of $18.07. The firm has a 50 day moving average of $12.37 and a 200 day moving average of $13.48. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares in the last quarter. SteelPeak Wealth LLC grew its holdings in Day One Biopharmaceuticals by 9.8% during the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after buying an additional 1,550 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in Day One Biopharmaceuticals by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock valued at $346,000 after buying an additional 1,805 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock valued at $454,000 after buying an additional 1,894 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in Day One Biopharmaceuticals during the 4th quarter valued at approximately $27,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on DAWN shares. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America reduced their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.